Palshof T, Mouridsen H T, Daehnfeldt J L
Recent Results Cancer Res. 1980;71:185-9. doi: 10.1007/978-3-642-81406-8_28.
In an attempt to clarify the value of adjuvant endocrine therapy as an alternative to other treatment modalities, we have started two controlled, prospective, double-blind trials, the Copenhagen Breast Cancer Trials. In these studies postmenopausal women are randomised after primary local treatment to treatment with DES, tamoxifen, or placebo. Premenopausal women are similarly randomised to receive treatment with tamoxifen or placebo. Entry to the trials was closed in March 1978, when 343 patients had entered the studies. The preliminary results indicate that postmenopausal patients with ER+ tumours benefit from adjuvant treatment with tamoxifen. Adjuvant treatment with DES seems to be effective in ER- postmenopausal patients. In postmenopausal patients the ER+ tumors have a lower rate of recurrence. At present these preliminary results do not permit definite conclusions.
为了阐明辅助内分泌治疗作为其他治疗方式替代方案的价值，我们启动了两项对照、前瞻性、双盲试验，即哥本哈根乳腺癌试验。在这些研究中，绝经后女性在进行原发性局部治疗后被随机分配接受己烯雌酚、他莫昔芬或安慰剂治疗。绝经前女性同样被随机分配接受他莫昔芬或安慰剂治疗。试验于1978年3月结束入组，当时有343名患者进入研究。初步结果表明，雌激素受体（ER）阳性肿瘤的绝经后患者从他莫昔芬辅助治疗中获益。己烯雌酚辅助治疗似乎对ER阴性的绝经后患者有效。在绝经后患者中，ER阳性肿瘤的复发率较低。目前，这些初步结果尚无法得出明确结论。
